Subscribe to get our latest investment news and insights straight to your inbox.

    IMPQ December 2021 Monthly Report & Update

    finder green etf
    IMPQ Monthly Report
    • IMPQ was up 2.3% net of fees in December, outperforming the benchmark return by 0.9%.
    • It is almost three years since the inception of the Fund. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest with a focus on shaping a better future. Since inception in May 2019, the Fund has delivered a 18.9% p.a. return net of fees, outperforming the benchmark by 7.6% p.a.
    • Positive contributors this month include Genetic Signatures (+36.1%), Telix Pharmaceuticals (+17.4%) and 3P Learning (+17.4%).
    • Negative contributors this month include Nitro Software (-29.8%), Janison Education (-5.7%) and Imricor (-14.8%)
    Performance
    Month (%)Quarter (%)FYTD (%)1 Year (%)2 Year (%)Since Inception* (% p.a.)Since Inception Cumulative* (%)
    eInvest Better Future Fund2.31.77.016.819.618.957.2
    S&P/ASX Small Ordinaries Index1.42.05.516.913.011.332.3
    Added value (detracted)0.9-0.31.5-0.16.67.624.9

    ^Inception date was 23 May 2019. IMPQ returns are calculated using net asset value per unit at the start and end of the specified period and do not reflect the brokerage or the bid-ask spread that investors incur when buying and selling units on the ASX. Past performance is not a reliable indicator of future performance.

    Better Future Highlights

    Telix Pharmaceuticals was up strongly during the month after announcing that the US Food and Drug Administration (‘FDA”) had approved Telix’s prostate cancer imaging product, Illucix. Obtaining FDA approval is a challenging process and this is a significant milestone for the company.

    Importantly, the Illucix product has also recently been included in the US NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer which means that patients will be able to start benefiting from the improved technology in the coming months. The Illucix technology has been recognised as superior to conventional imaging with CT or MRI. The technology can give physicians the ability to visualise tumour cells, including very small metastases.

    Prostate cancer is the second leading cancer in men in the United States with nearly 250,000 cases estimated in 2021.  Prostate cancer was also the second leading cause of cancer death in men in 2020.

    Illucix has also been approved by the Therapeutic Goods Administration in Australia and regulatory authorities in Brazil and is in the late stages of the approval process in the EU.

    Telix, which has returned over 100% over the last 12 months is a good example of what the Better Future Trust is striving to achieve – strong, consistent returns while shaping a better future – in this case for patients with prostate cancer.

    Fund Review

    IMPQ was up 2.3% net of fees in December, outperforming the benchmark return by 0.9%.

    The Fund has been running for almost 3 years. It is a key goal of the Fund to demonstrate that there is no performance trade-off to invest for shaping a better future. Since inception in February 2018, IMPQ has delivered a 18.9% p.a. return net of fees, outperforming the benchmark by 7.6% p.a.

    Positive contributors this month include Genetic Signatures (+36.1%), Telix Pharmaceuticals  (+17.4%) and 3P Learning (+17.4%).

    Negative contributors this month include Nitro Software (-29.8%), Janison Education  (-5.7%) and Imricor (-14.8%).

    Genetic Signatures provided a trading update in which it announced that the company’s EasyScreen product which is a more efficient PCR test for COVID-19 had been a beneficiary of increased PCR testing due to the rapid spread of the Omicron variant. It also announced that the company’s European sales team had been engaging with customers in relation to other EasyScreen products and had received the first order for EasyScreen enteric kits which are used to detect gastrointestinal viruses more efficiently than traditional methods.  There are also two other European clients close to concluding trials of the EasyScreen enteric kits.

    As discussed in the Better Future Highlight section earlier, Telix Pharmaceuticals announced that it had received US Food and Drug Administration approval for the company’s Illucix product which is used to detect prostate cancer.

    Nitro Software declined after US comparables DocuSign and Adobe announced weaker than expected results which indicated that growth rates in the company’s markets were slowing from very high levels. While it would be preferable for the end markets to be continuing their strong growth, we note that the Nitro business is far smaller than that of these large market participants and that Nitro is seeking to capture market share from these competitors.

    Imricor Medical Systems was weaker due to concerns that the emergence of the Omicron COVID-19 variant in Europe may impact the company’s ability to execute on its sales pipeline. On Christmas Eve the company announced that it had signed two world-renowned institutions as new customers in Berlin, Germany – The German Heart Centre Berlin and the Charite Medical University Virchow-Klinikum Campus.

    During the month we reduced our holding in Charter Hall Group  following very strong performance and added to our positions in APM and Nitro Software upon weakness.

    At month end, the portfolio held 51 stocks and cash of 8.8%.

    At December end, the weighted average Perennial-derived Environmental, Social, Governance and Engagement (“ESGE”) Score of the Fund was 7.2 which is 26% higher than the benchmark ESGE Score of 5.7.

    ESG Activity

    Our ESG activity during the month included:

    • During December, the Better Future team targeted gender diversity on boards. We emailed all companies that are yet to reach our target of 30% women on the board of directors. We received positive and engaged responses from over 70% of those emailed. We expect to see improved outcomes in the coming 12 months. Some positive examples included Calix and Alpha HPA, each of which indicated that they are actively looking to improve gender diversity across both their boards and the broader business.
    • In a meeting with EROAD we discussed carbon footprinting and ESG reporting.
    • We had a sustainability meeting with Charter Hall in which we discussed the approach of the company and Charter Hall Social Infrastructure REIT to ESG and sustainability, including carbon emissions and TCFD reporting, SDGs, corporate governance, modern slavery, diversity and gender pay gaps.
    • We met with HealthCo Healthcare and Wellness REIT to discuss the company’s approach to ESG and sustainability, including the company’s objective to invest to bring health services to underserved communities, gender diversity targets and carbon reduction targets.

    This Analysis done on the Better Future Trust portfolio as at 31 August 2021 by the Sustainable Platform

    To read more about eInvest Better Future Fund (Managed Fund) ASX: IMPQ, click here.

    Interested in purchasing units in the fund? Contact your financial adviser or simply purchase via your online broker, and as always read the PDS for more information. This can be found here. 

    Past performance is not a reliable indicator of future performance. Please read the PDS prior to investing. This information is general in nature and is subject to the terms and conditions outlined here.